Fatima Abji1, Justine Yang Ye1, Richard J Cook2, Katerina Oikonomopoulou1, Vinod Chandran3,4,5,6,7. 1. Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, University Health Network, University of Toronto, 399 Bathurst Street 1E-416, Toronto, Ontario, M5T 2S8, Canada. 2. Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Canada. 3. Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, University Health Network, University of Toronto, 399 Bathurst Street 1E-416, Toronto, Ontario, M5T 2S8, Canada. vinod.chandran@uhnresearch.ca. 4. Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Canada. vinod.chandran@uhnresearch.ca. 5. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. vinod.chandran@uhnresearch.ca. 6. Institute of Medical Science, University of Toronto, Toronto, Canada. vinod.chandran@uhnresearch.ca. 7. Department of Medicine, Memorial University, St. John's, Canada. vinod.chandran@uhnresearch.ca.
Abstract
INTRODUCTION/ OBJECTIVES: Intra-articular corticosteroid (IAS) injections are often used for the immediate relief of pain and inflammation in the joint of psoriatic arthritis (PsA) patients. However, studies identifying factors that predict response to the IAS injections are lacking. We aimed to assess the usefulness of serine proteinase activity measurements in PsA synovial fluid (SF) samples obtained at the time of injection in predicting clinical response. METHODS: The PsA patients with available SF samples from the knee joint were identified from the University of Toronto PsA cohort. Clinical response was defined as an absence of tenderness or swelling in the injected joint at the first post-injection visit, at either 3 or 6 months. SF proteinase activity was determined by measuring cleavage of fluorogenic tri-peptide substrates for trypsin-like (VPR-AMC and VLK-AMC) and chymotrypsin-like (AAPF-AMC) serine proteinases. Generalized estimating equation (GEE) models were used to investigate factors associated with response. RESULTS: A total of 32 patients with 60 injected joints and data available for follow-up at 3 or 6 months were included in the analysis, with 25 (41.7%) injected joints resulting in clinical response. Age, sex, active joint count, systemic medications and SF serine proteinase activity at the time of injection were included as covariates. Only treatment with biologics was significantly associated with response at 3 or 6 months in the multivariate reduced model (OR 3.02, p = 0.027). CONCLUSIONS: We could not demonstrate an association between SF serine proteinase activity and response to IAS injection. Biologic agents significantly improve the likelihood of achieving clinical response.
INTRODUCTION/ OBJECTIVES: Intra-articular corticosteroid (IAS) injections are often used for the immediate relief of pain and inflammation in the joint of psoriatic arthritis (PsA) patients. However, studies identifying factors that predict response to the IAS injections are lacking. We aimed to assess the usefulness of serine proteinase activity measurements in PsA synovial fluid (SF) samples obtained at the time of injection in predicting clinical response. METHODS: The PsApatients with available SF samples from the knee joint were identified from the University of Toronto PsA cohort. Clinical response was defined as an absence of tenderness or swelling in the injected joint at the first post-injection visit, at either 3 or 6 months. SF proteinase activity was determined by measuring cleavage of fluorogenic tri-peptide substrates for trypsin-like (VPR-AMC and VLK-AMC) and chymotrypsin-like (AAPF-AMC) serine proteinases. Generalized estimating equation (GEE) models were used to investigate factors associated with response. RESULTS: A total of 32 patients with 60 injected joints and data available for follow-up at 3 or 6 months were included in the analysis, with 25 (41.7%) injected joints resulting in clinical response. Age, sex, active joint count, systemic medications and SF serine proteinase activity at the time of injection were included as covariates. Only treatment with biologics was significantly associated with response at 3 or 6 months in the multivariate reduced model (OR 3.02, p = 0.027). CONCLUSIONS: We could not demonstrate an association between SF serine proteinase activity and response to IAS injection. Biologic agents significantly improve the likelihood of achieving clinical response.
Authors: Jean-Marie Delaissé; Thomas L Andersen; Michael T Engsig; Kim Henriksen; Tine Troen; Laurence Blavier Journal: Microsc Res Tech Date: 2003-08-15 Impact factor: 2.769
Authors: Francesco Carubbi; Luigi Zugaro; Paola Cipriani; Armando Conchiglia; Lorenzo Gregori; Cristino Danniballe; Maria Letizia Pistoia; Vasiliki Liakouli; Piero Ruscitti; Francesco Ciccia; Giovanni Triolo; Carlo Masciocchi; Roberto Giacomelli Journal: Int J Immunopathol Pharmacol Date: 2015-12-18 Impact factor: 3.219
Authors: Deepak R Jadon; Raj Sengupta; Alison Nightingale; Hui Lu; Juliet Dunphy; Amelia Green; James T Elder; Rajan P Nair; Eleanor Korendowych; Mark A Lindsay; Neil J McHugh Journal: Arthritis Res Ther Date: 2017-09-21 Impact factor: 5.156